UK markets closed

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.39+3.87 (+10.05%)
As of 02:41PM EDT. Market open.
Sign in to post a message.
  • D
    DIPP
    Can’t believe this site just gave me a 43% winner. (http://market-engross.club)
  • J
    Jeffrey
    Massively undervalued. $3bn market cap with $1.6bn cash. Revenues of $460m-$470m expected this year. Clinical volumes up 47%. Shield LDT now launched.
  • E
    End2War
    This stock has suffered a sharp PPS decline to a level that it now looks to be a very good bargain basement play. It has great technology and an enormous TAM, and the EPIC deal is going to speed it's sales growth significantly, as it expands its product offerings. It is the clear leader in "liquid biopsy" and the many ways this technology can be used is quite promising for huge profits over time as sales growth is set to explode, IMO. Please don't listen to the short sellers that have latched onto this stock as it suffered a price decline in a difficult market environment. If you buy and hold till the market swings into a more positive mood, it will be recognized for the growth and profit potential that it has. Test results coming by the end of the year should help PPS from here. With its current $3 B MC and strong sales growth, it should be expected to provide a great investment for those that buy and patiently hold. GLTY and please do your own research and DD and never base your decisions on posters.
  • e
    egghead
    I am not understanding what Doctor would prescribe a test that is not FDA approved? Am I missing something?
  • J
    Janet
    Has the FDA approved this test? Has the test been accepted by any insurance networks?
  • F
    Frank
    Sell a big loss. Just hold onto it
    Hope one day it may go up again
  • K
    Kalvin
    worse investment ever
  • J
    Joe
    On the other hand profitability for testing isn't easy :
    Illumina (NASDAQ:ILMN) saw its Q1 2022 net income decline ~41% compared to the prior-year period due to a significant operating loss from its GRAIL division, which was acquired in August 2021.
  • B
    Benjo
    Single Digit
  • O
    Oldguy794
    EXAS tried marketing a non approved early version of a stool CRC screening test called PreGenPlus in 2007. FDA was not pleased and sent EXAS a letter saying they believed regulatory approval was required for their device. Market responded as you would expect and the stock was punished.
  • S
    Steven
    If the ECLIPSE test doesn’t produce outstanding results, this stock is DOA
  • J
    JimmieG
    Almost a 10% down day. Rock solid. Blame it on the he Nasdaq; everyone else does. Only off 66% from its high. Guess that is a Nasdaq thing too.
  • J
    JimmieG
    Strong move into earnings, only off 17% in a week. This life saver has it all, huh?
  • B
    Barnacle Barney
    How can any corporation in 'health care' be unprofitable ?
    Overpaid top management is one of the usual suspects.
  • F
    Francis
    It’s a long way reach that $123 target price. Can’t see that happening, regardless of valuation, underselling, overselling, or anything else.
  • D
    DoublinDown
    should really by $20. this has been so overvalued,. Taken my lumps elsewhere though
  • J
    Joe
    Huge mistake from being swept up from the noble goal of predictive diagnostics, while ignoring the company's performance.
    The question now is to hold and hope for a buyout, or sell into the bounce.
    Unless the find a way to become profitable, the euphoria of last year is gone.
  • J
    JimmieG
    Best hope GH does not have an AMRN moment after their report. Clearly showing losses on the books tomorrow is not going to make the share price go up. A negatively received earnings report will send this below $45.
  • n
    nbs415
    Down market due to margin calls, but great buying opportunity.